Home > Drugs A – Z > Rasagiline (By mouth)

Rasagiline (By mouth)

Treats Parkinson disease. This medicine is an MAOI.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Rasagiline is used alone or together with levodopa for the treatment of Parkinson's disease. Parkinson's disease is a condition of the brain that becomes worse over time and may cause movement problems, rigidity, tremors, and slowed physical movement. This medicine is only available with your doctor's prescription… Read more
Brand names include
Azilect
Drug classes About this
Antiparkinsonian

What works? Research summarized

Evidence reviews

Rasagiline for Parkinson's disease: a meta-analysis

Bibliographic details: Tong YS, Yang XL.  Rasagiline for Parkinson's disease: a meta-analysis. Chinese Journal of Evidence-Based Medicine 2014; 14(2): 205-210 Available from: http://www.cjebm.org.cn/oa/DArticle.aspx?type=view&id=20140212

Determining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review

BACKGROUND: Bradykinesia has a significant impact on the lives of Parkinson's disease (PD) patients. Consequently, treating this symptom is of particular concern for patients and clinicians. A number of studies have documented the efficacy of rasagiline in reducing the severity of PD symptoms.

Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data

The review concluded that rasagiline was efficacious for Parkinson's disease when compared with placebo but that the clinical significance of these data remained to be established. Despite some methodological and reporting limitations, these conclusions appear likely to be reliable.

See all (12)

Summaries for consumers

Treatment for fatigue in Parkinson's disease

At least one‐third of people with Parkinson's disease complain about fatigue. It is unclear what treatment is best to reduce fatigue in people with Parkinson's disease.

Monoamine oxidase B inhibitors compared with other treatments in early Parkinson's

Many of the symptoms of Parkinson's disease are due to the loss of certain groups of nerves in the brain, which results in the lack of a chemical called dopamine. Currently, there are several different treatments available for people with newly diagnosed Parkinson's including levodopa (Sinemet or Madopar) which is converted into dopamine in the brain, dopamine agonists (for example, ropinirole and pramipexole) which mimic the action of dopamine, and monoamine oxidase B (MAO‐B) inhibitors (selegiline or rasagiline) which reduce the breakdown of dopamine in the brain. Each of these types of drugs has theoretical advantages and disadvantages. For example, although a very good treatment, levodopa can cause involuntary movements (dyskinesia), painful cramps (dystonia) and a shortened response to each dose (motor fluctuations) after a while, whilst MAO‐B inhibitors and dopamine agonists may reduce the risk of these complications but are not so good at improving the symptoms of Parkinson's. At present, therefore, it is not clear which of these three groups of drugs should be prescribed when people with early Parkinson's first need treatment. We reviewed the trials that compared giving MAO‐B inhibitors with other types of medication in people with early Parkinson's to see if there was good evidence that MAO‐B inhibitors were the best treatment to offer. However, unfortunately we only identified two trials (593 patients) so there was only limited evidence. The results showed that MAO‐B inhibitors were less good at improving the symptoms of Parkinson's than either levodopa or dopamine agonists but that they may reduce motor fluctuations compared with levodopa, though not compared with dopamine agonists. MAO‐B inhibitors did, however, have fewer major side effects than some dopamine agonists.

PubMed Health Blog...

read all...